Core Viewpoint - Zomedica is focusing on its R&D strategy to support scalable growth and enhance long-term shareholder value through an upcoming investor webinar [1] Group 1 - The company is an animal health firm that provides innovative diagnostic and therapeutic devices for both equine and companion animals [1] - The next installment of the "Fourth Friday at Four" investor webinar series is scheduled for February 27, 2026, at 4:00 p.m. Eastern Time [1]

Core Viewpoint - AbbVie and Medtronic are highlighted as healthcare stocks that consistently grow their dividends, supported by healthy free cash flow, despite the general trend of lower dividend yields in the healthcare sector [1][3][15]. AbbVie - AbbVie has a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, qualifying it as a Dividend King [4]. - The company reported revenue of $15.8 billion in the third quarter, a 9% year-over-year increase, although earnings per share (EPS) declined by 38% to $1.86 due to higher R&D spending [6]. - AbbVie has successfully transitioned from reliance on Humira, which previously accounted for 63% of its revenue, to a diversified portfolio including Rinvoq and Skyrizi, with Skyrizi generating $4.7 billion in the latest quarter [7]. - The oncology segment now contributes nearly 11% to AbbVie's revenue, bolstered by new therapies [8]. - AbbVie's dividend payout ratio is 58%, but its free cash flow per share of $11.11 supports its annual dividend payout of $6.92 [9]. Medtronic - Medtronic, with a market cap of $132 billion, is the largest stand-alone medical device maker, producing a wide range of medical equipment [10]. - The company reported revenue of $9 billion in the second quarter of fiscal 2026, a 6.6% year-over-year increase, with EPS rising 8% to $1.07 [13]. - Medtronic's dividend yield is approximately 2.76%, and it has increased its dividend for 48 consecutive years, with a payout ratio of 69% [14]. - The company plans to spin off its diabetes business, which accounts for only 8% of revenue, without impacting its dividend [14]. Industry Insights - Healthcare companies, unlike utilities, must continuously invest in R&D due to the nature of their products, which often face patent expirations and generic competition [2]. - AbbVie and Medtronic leverage their size and diversification to maintain revenue growth and dividend increases, mitigating risks from potential downturns in specific segments [15][16].

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% year-over-year [6][12] - For the full year 2025, total sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates [14] - Business EPS growth was strong at 26.7%, indicating effective operational leverage [12] - Business gross margin expanded by 1.8 percentage points to 77.5%, driven by a favorable product mix and operational efficiencies [14] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines generated EUR 5.7 billion in sales, with a growth of 34% in 2025 [4][6] - Dupixent sales reached EUR 4.2 billion in Q4 and EUR 15.7 billion for the full year, with over 30% increase in patient numbers [7][8] - Beyfortus sales grew by 9.5% to EUR 1.8 billion, driven by geographic expansion [8][9] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full year sales of EUR 7.9 billion [8] - The U.S. market share for influenza vaccines increased, particularly with Fluzone High-Dose and Flublok [8] - Beyfortus has protected over 11 million babies in more than 45 countries, preventing an estimated 200,000 hospitalizations [9] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma entity, focusing on business development and M&A opportunities [4] - Strategic acquisitions, including Vicebio and Dynavax Technologies, are aimed at enhancing the vaccine portfolio and expanding into older adult demographics [9][10] - The company plans to continue investing in manufacturing capacity to meet growing patient demand [14] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver profitable growth close to 2025 levels, with high single-digit sales growth anticipated [17][18] - The company is preparing for potential challenges in vaccine sales and is focused on maintaining a stable G&A expense structure [18] - Management highlighted the importance of innovation and collaboration in achieving sustainable healthcare goals [10] Other Important Information - The company completed a EUR 5 billion share buyback program and proposed a 5% increase in dividends for the 31st consecutive year [17] - Free cash flow returned to strong levels at EUR 8.1 billion, representing 18.5% of sales, with a target of reaching at least 20% in the medium term [15] Q&A Session Summary Question: Can you elaborate on the Dupixent rollout and its competition? - Management reported strong performance with 25% year-over-year growth for Dupixent, driven by new indications like CSU and COPD [30][31] Question: What is the growth outlook for Beyfortus in 2026? - Management expressed optimism about Beyfortus performance, noting its availability in over 45 countries and a positive real-world evidence publication [34][36] Question: What are the prospects for Amlitelimab and its market penetration? - Management remains confident in Amlitelimab's potential, emphasizing its novel mechanism and the importance of ongoing data collection [39][41] Question: How is the company addressing the recent changes in the U.S. pediatric vaccination schedule? - Management acknowledged potential confusion but emphasized proactive engagement with healthcare providers to maintain vaccination rates [77][78] Question: What is the strategy for capital allocation moving forward? - Management indicated a dynamic allocation strategy guided by AI, focusing on maximizing value from investments [60]

Core Insights - Planet Labs (PL) emphasizes research and development (R&D) as a key driver of long-term growth and competitiveness, operating the largest fleet of Earth-observation satellites globally [1] R&D Investment - R&D expenses are classified as costs related to advancing technology, platform development, and new product iterations, accounting for 41% of revenues in fiscal 2025 [2][9] - Continuous innovation in satellite hardware, launch cadence, data infrastructure, and analytics software is essential for maintaining competitive advantage [3] - R&D spending is expected to increase, enhancing product differentiation and pricing power while lowering unit costs and extending satellite lifetimes [4][5] Competitive Landscape - R&D is crucial for the long-term competitiveness of peers like Rocket Lab (RKLB) and BlackSky Technology (BKSY), with Rocket Lab focusing on launch reliability and next-gen vehicles, and BlackSky enhancing imaging and analytics capabilities [6][7] Financial Performance - PL's stock has gained 494.2% over the past year, outperforming the industry [8] - The stock is currently overvalued, trading at a price-to-sales multiple of 22.16, significantly higher than the industry average of 2.39 [10] Earnings Estimates - There has been no movement in the Zacks Consensus Estimate for PL's fiscal fourth-quarter 2026 and fiscal first-quarter 2027 EPS over the last 30 days, with estimates indicating year-over-year increases for fiscal 2026 and 2027 [11][12]

Core Viewpoint - Amphastar Pharmaceuticals is transitioning towards higher-value proprietary products while maintaining a focus on internal development and strategic acquisitions to enhance growth and profitability [2][5][13]. Growth Strategy - The company's growth strategy is two-pronged: internal development and strategic acquisitions, including the transformative acquisition of Baqsimi and prior acquisitions like the Armstrong facility [1][3]. - Amphastar aims for a 50% proprietary product mix by 2026, shifting from a historical pipeline that was 63% generic [5][6]. Product Development and Pipeline - The company is advancing a peptide pipeline with several promising candidates, including AMP-007 (metered-dose inhaler) expected to launch in mid-2026 and AMP-004 (insulin aspart) projected for 2027 [4][10]. - Four new chemical entities (NCEs) are in development, showing promising preclinical or early clinical data [4][8]. Financial Projections - Peak sales guidance for Baqsimi is set at $250–$275 million, with expectations of mid-single-digit growth this year [3][14]. - The company plans to exit unprofitable international markets to improve margins and forecasts high single-digit growth for Primatene Mist [3][15]. Research and Development Focus - Amphastar consistently invests $60–$75 million annually in R&D, focusing on proprietary programs, including AMP-105 and AMP-107, which target significant market opportunities [8][12]. - The company is evolving its pipeline in response to increased competition in complex generics, aiming for a mix of 50% proprietary, 35% biosimilar, and 15% generic by 2026 [6][20]. Market Position and Competitive Advantage - The acquisition of Baqsimi has strengthened Amphastar's position in the proprietary commercial Rx market and expanded its international footprint [13][18]. - The company has captured a majority of the prescription market for ready-to-use glucagon and is focused on increasing penetration among insulin users [18][19].

Core Insights - Merit Medical Systems, Inc. (MMSI) is positioned for growth due to a strong product portfolio and solid performance in 2025, despite facing macroeconomic headwinds and forex volatility [2] - The company has experienced a 9% decline in shares this year, while the industry has grown by 12.5% and the S&P 500 has increased by 18.3% [2] Company Performance - Merit Medical has a market capitalization of $5.2 billion and projects a 9.6% growth rate over the next five years, with an average earnings surprise of 14.09% over the past four quarters [3] - The third quarter saw a 7.8% organic constant-currency growth, driven by strong performance in the Cardiovascular segment, particularly in Peripheral and Cardiac Intervention franchises [5][9] Positive Drivers - The demand for embolics like Embosphere and QuadraSphere remains robust, with balanced growth across the U.S., EMEA, and APAC regions, reducing dependence on any single market [6] - The gross margin reached a record 53.6%, with a 267-basis-point year-over-year expansion attributed to favorable product mix, pricing discipline, and improved distribution costs [10] - The company generated $52.5 million in quarterly free cash flow, up 38% year over year, while continuing to invest in R&D and acquisitions [10] Growth Catalysts - WRAPSODY CIE is gaining traction post NTAP reimbursement, with early adoption tracking ahead of expectations, which could significantly expand the addressable market [11][12] - The potential approval of Transitional Pass-Through (TPT) reimbursement for outpatient procedures could further accelerate WRAPSODY CIE's revenue growth [12] Key Challenges - Tariff-related costs could impact earnings significantly, with estimates ranging from $7.6 million to $16 million in 2025, depending on global trade policy developments [13] - Sales in China declined by 1% year over year, reflecting broader macroeconomic weakness, while OEM demand remains volatile, affecting revenue predictability [15][16] - Integration challenges from ongoing acquisitions could pose risks to near-term performance, particularly in the Endoscopy segment [17][18] Estimate Trends - The Zacks Consensus Estimate for earnings per share (EPS) for 2025 has increased by 4 cents to $3.73, with fourth-quarter 2025 revenue estimates at $387.5 million, indicating a 9.1% rise from the previous year [19]

Some of the wealthiest individuals in tech have pledged as much as $1 billion to CERN to fund a proposed successor to the Large Hadron Collider, as the research institute turns to private backers to back future breakthroughs https://t.co/Dv8JNGYUGb ...

Core Insights - The aerospace and defense sector is facing challenges due to potential executive orders that may impose penalties on defense primes, making profitability difficult given current operating margins of 10% and cash margins of 5% [2][4] - The balance between research and development (R&D) investment and shareholder returns is highlighted, with defense primes investing approximately $40 billion in R&D and capital expenditures while returning $50 billion through dividends and buybacks, indicating a 1.3% investment to return ratio [4][5] - The commercial aerospace market is projected to grow, with aircraft needs increasing by 3% and aftermarket services by 8-10%, making companies like GE and RTX attractive investments [7][8] Investment Dynamics - The lack of clarity in defense budgets complicates investment cycles for defense primes, which do not have 5-year budgets, impacting their ability to generate returns [8][9] - International growth is seen as a significant upside, with NATO spending potentially increasing from 2% to 3.5%, translating to $280 billion in investments for defense primes, benefiting both U.S. and European contractors [10][11] - RTX has a notable exposure to European spending, with 44% of its defense backlog linked to this market, indicating strong international growth potential [11] Geopolitical Influence - The current geopolitical climate, including U.S. defense budgets growing by 3-5%, is influencing the defense sector, with international sales typically yielding higher margins for American defense primes [10][13] - The Trump administration's support for both large and small contractors has led to increased funding and innovation within the defense sector, resulting in a rise in defense tech IPOs [14][15] - The global threat environment is broadening the focus for defense contractors beyond traditional regions, emphasizing the need for a diverse playbook to address various geopolitical challenges [15]

R&D Leadership and Organization - Sanofi is building a skilled and thoughtful R&D leadership team and organization[5, 6, 7, 106] - The company is strengthening capabilities across research, translational medicines, development, medical, regulatory affairs, and digital[106] Pipeline Highlights and Approvals - Sanofi achieved three new medicine and vaccine approvals in 2025: Qfitlia, Wayrilz, and Nuvaxovid[12, 13, 106] - Dupixent showed benefit across relevant endpoints in Bullous pemphigoid, with 12.2% difference in patients achieving sustained remission compared to placebo + OCS and 27.8% difference in patients with ≥4-point improvement in PP-NRS[20, 21] - Dupixent clinically meaningfully improved radiographic, endoscopic, and symptoms of Allergic fungal rhinosinusitis, with lower proportion of patients receiving SCS treatment and/or surgery[24] - Amlitelimab (OX40L mAb) in AD: first phase 3 study met primary and key secondary endpoints, showing clinically meaningful improvement in skin clearance and disease severity[26] - Brivekimig (TNFaxOX40L Nanobody®) in HS: phase 2a study achieved primary objective, with 54% of participants achieving HiSCR75[28, 29] - Itepekimab (IL33 mAb) in COPD: AERIFY-1 study showed a significant reduction in moderate or severe exacerbations of 27.1% at Week 52 with Q2W dosing across EOS level[38] - Duvakitug (TL1A mAb) in CD/UC: positive and encouraging phase 2b data presented at ECCO 2025, with 48% clinical remission in Crohn's disease high dose group[46, 47] - Fluzone HD demonstrated superior protection vs standard-dose influenza vaccines against hospitalization in older adults, including a -31.9% reduction in laboratory confirmed influenza hospitalization[75] - Monovalent RSV (mRNA) vaccine showed 74.9% efficacy against RSV LRTD in a phase 2 study[80] Pipeline Replenishment and Digital Transformation - Sanofi is progressing on pipeline entries augmented by strategic business development[107] - The R&D digital plan aims at reducing cycle times across the R&D value chain by more than 40%[94, 95, 107] Upcoming News Flow - Sanofi anticipates >15 regulatory decisions, >30 regulatory submissions, and >15 phase 3 data readouts in 2026 and 2027[108]

Group 1 - BofA analyst Michael Ryskin has lowered the price target on Tempus AI (TEM) to $80 from $90 while maintaining a Neutral rating on the shares [1] - The firm is updating price targets for Life Sciences & Diagnostic Tools stocks under its coverage, indicating a shift in market conditions [1] - Headwinds are expected to fade, with markets anticipated to normalize by 2026, suggesting a potential recovery in the sector [1] Group 2 - The firm believes that the biggest upside for the sector will come from a return to spending by Biopharma, which could positively impact companies with higher exposure to research and development [1]